Atlas FDA

Thoraflex Hybrid

FDA premarket approval P210006/S012 · decided 2025-04-09

Approval details

PMA number
P210006
Supplement
S012
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Thoraflex Hybrid
Generic name
Hybrid stent graft, thoracic aortic lesion treatment
Applicant
Vascutek, Ltd.
Date received
2025-03-10
Decision date
2025-04-09
Days to decision
30 days
Decision code
OK30
Product code
QSK
Advisory committee
Cardiovascular
Expedited review
No
Location
Inchinnan
Statement
changes to the bioburden and cleanroom monitoring processes and addition of a new manufacturing equipment for the Thoraflex Hybrid

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Gelweave™ Vascular Prostheses (K241550)Vascutek, Ltd.2025-02-27
Gelsoft™ Plus Vascular Prostheses (K241070)Vascutek, Ltd.2024-11-15
Vascutek Gelsoft Plus ERS Vascular Graft (K202703)Vascutek, Ltd.2021-04-06
Vascutek Gelseal Patch, Vascutek Gelsoft Patch, Vascutek Thin Wall Carotid Patch (K200955)Vascutek, Ltd.2020-07-08
Gelseal Vascular Grafts, Gelsoft Vascular Grafts, Gelsoft Plus Vascular Grafts (K162803)Vascutek, Ltd.2017-07-14
Gelweave Vascular Grafts (K162794)Vascutek, Ltd.2017-06-30
GELWEAVE BRANCHED VASCULAR GRAFTS WITH RADIOPAQUE MARKERS (K093817)Vascutek, Ltd.2010-01-07
MAXIFLO, TAPERFLO (K092863)Vascutek, Ltd.2009-10-08